After Today’s Huge Decline, Is Theralase Technologies Inc.’s Near-Term Analysis Negative?

 After Today's Huge Decline, Is Theralase Technologies Inc.'s Near Term Analysis Negative?

The stock of Theralase Technologies Inc. (CVE:TLT) is a huge mover today! About 225,700 shares traded hands. Theralase Technologies Inc. (CVE:TLT) has risen 6.00% since October 31, 2016 and is uptrending. It has outperformed by 0.77% the S&P500.
The move comes after 7 months negative chart setup for the $36.00M company. It was reported on Nov, 30 by Barchart.com. We have $0.26 PT which if reached, will make CVE:TLT worth $1.08 million less.

More recent Theralase Technologies Inc. (CVE:TLT) news were published by: Midasletter.com which released: “Theralase Technologies Inc: A Cure for Cancer?” on February 24, 2014. Also Business.Financialpost.com published the news titled: “Podcast: Theralase Technologies CEO on using light for pain and cancer treatment” on June 15, 2016. Midasletter.com‘s news article titled: “Theralase Technologies Inc. Upends Cancer Research with Immune System Response” with publication date: June 11, 2014 was also an interesting one.

Theralase Technologies Inc. is a biotech firm focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds to destroy cancer. The company has a market cap of $36.00 million. The Firm operates through two divisions: Therapeutic Laser Technology (TLT) division and Photo Dynamic Therapy (PDT) division. It currently has negative earnings. The TLT division designs, develops, makes and markets super-pulsed laser technology indicated for the healing of chronic knee pain.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment